Literature DB >> 11304496

Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo.

I Hamanaka1, Y Saito, H Yasukawa, I Kishimoto, K Kuwahara, Y Miyamoto, M Harada, E Ogawa, N Kajiyama, N Takahashi, T Izumi, R Kawakami, I Masuda, A Yoshimura, K Nakao.   

Abstract

CIS (cytokine-inducible SH2 protein), SOCS (suppressor of cytokine signaling), or SSI (signal transducers and activators of transcription [STAT]-induced STAT inhibitor) proteins are a family of cytokine-inducible negative regulators of cytokine signaling via Janus kinase (JAK)-STAT pathways. Given the evidence that the JAK-STAT pathway plays a critical role in the cardiovascular system, the primary objective of this study was to assess the effects of the CIS family on JAK-STAT signaling in the cardiovascular system in rats treated with cardiotrophin-1 (CT-1), an interleukin-6 family of cytokines. Intravenous injection of 20 microgram/kg body weight of CT-1 induced a transient, marked increase in STAT3 activation in various tissues, including heart and lung, and subsequent upregulation of 2 members of the CIS family, JAK-binding protein (JAB)/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3, in the same tissues. It was also observed that CIS3 was directly associated with JAK2 in vivo. Pretreatment with the same dose of CT-1 60 minutes before significantly attenuated the STAT3 activation induced by a second injection of CT-1. We previously reported that intravenous injection of CT-1 results in the nitric oxide (NO)-dependent hypotension accompanied by the induction of inducible NO synthase mRNA. In rats pretreated with CT-1, the induction of inducible NO synthase mRNA or hypotension by subsequent CT-1 injection was not observed. Forced expression of JAB or CIS3, but not other CISs, directly blocked CT-1-induced STAT3 activation in 293 cells. These results suggest that JAB and CIS3 serve as endogenous inhibitors of CT-1-mediated JAK-STAT signaling in the cardiovascular system in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304496     DOI: 10.1161/hh0701.088512

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  15 in total

Review 1.  The central role of SOCS-3 in integrating the neuro-immunoendocrine interface.

Authors:  C J Auernhammer; S Melmed
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway.

Authors:  Antonio Cittadini; Maria Gaia Monti; Guido Iaccarino; Maria Carmina Castiello; Alfonso Baldi; Eduardo Bossone; Salvatore Longobardi; Alberto Maria Marra; Valentina Petrillo; Lavinia Saldamarco; Matthew John During; Luigi Saccà; Gianluigi Condorelli
Journal:  Cardiovasc Res       Date:  2012-08-08       Impact factor: 10.787

Review 3.  The molecular details of cytokine signaling via the JAK/STAT pathway.

Authors:  Rhiannon Morris; Nadia J Kershaw; Jeffrey J Babon
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

4.  Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways.

Authors:  H Yasukawa; M Hoshijima; Y Gu; T Nakamura; S Pradervand; T Hanada; Y Hanakawa; A Yoshimura; J Ross; K R Chien
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

5.  Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.

Authors:  Hajime Isomoto; Justin L Mott; Shogo Kobayashi; Nathan W Werneburg; Steve F Bronk; Serge Haan; Gregory J Gores
Journal:  Gastroenterology       Date:  2006-11-07       Impact factor: 22.682

6.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

Review 7.  SOCS3: A novel therapeutic target for cardioprotection.

Authors:  Hideo Yasukawa; Takanobu Nagata; Toyoharu Oba; Tsutomu Imaizumi
Journal:  JAKSTAT       Date:  2012-10-01

8.  Cardiac-Specific SOCS3 Deletion Prevents In Vivo Myocardial Ischemia Reperfusion Injury through Sustained Activation of Cardioprotective Signaling Molecules.

Authors:  Takanobu Nagata; Hideo Yasukawa; Sachiko Kyogoku; Toyoharu Oba; Jinya Takahashi; Shoichiro Nohara; Tomoko Minami; Kazutoshi Mawatari; Yusuke Sugi; Koutatsu Shimozono; Sylvain Pradervand; Masahiko Hoshijima; Hiroki Aoki; Yoshihiro Fukumoto; Tsutomu Imaizumi
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 9.  Role of cytokine signaling during nervous system development.

Authors:  Alyaa Mousa; Moiz Bakhiet
Journal:  Int J Mol Sci       Date:  2013-07-04       Impact factor: 5.923

10.  SOCS3 deficiency in cardiomyocytes elevates sensitivity of ischemic preconditioning that synergistically ameliorates myocardial ischemia reperfusion injury.

Authors:  Shoichiro Nohara; Mai Yamamoto; Hideo Yasukawa; Takanobu Nagata; Jinya Takahashi; Koutatsu Shimozono; Toshiyuki Yanai; Tomoko Sasaki; Kota Okabe; Tatsuhiro Shibata; Daiki Akagaki; Kazutoshi Mawatari; Yoshihiro Fukumoto
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.